Associations - PIK3CA mutation

PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	BKM120 Sensitive: B - Late Trials	BKM120 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials	GDC-0068 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	panitumumab Resistant: B - Late Trials	panitumumab Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials	neratinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials	lapatinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials	trastuzumab Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	atezolizumab + cobimetinib Sensitive: B - Late Trials	atezolizumab + cobimetinib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials	everolimus Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: B - Late Trials	erlotinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Uterine Cancer Uterine Cancer	PIK3CA mutation PIK3CA mutation	Uterine Cancer Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria	copanlisib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria	MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria	palbociclib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	CYH33 Sensitive: C2 – Inclusion Criteria	CYH33 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria	MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria	GDC-0032 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	alpelisib Sensitive: C2 – Inclusion Criteria	alpelisib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials	U3-1402 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Urothelial Cancer Urothelial Cancer	PIK3CA mutation PIK3CA mutation	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	temsirolimus Sensitive: C3 – Early Trials	temsirolimus Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	X-396 Resistant: C3 – Early Trials	X-396 Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	bevacizumab Sensitive: C3 – Early Trials	bevacizumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: C3 – Early Trials	ribociclib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials	fulvestrant + anastrozole Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials	CDK6 inhibitor Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials	CDK4 inhibitor Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Liposarcoma Liposarcoma	PIK3CA mutation PIK3CA mutation	Liposarcoma Liposarcoma	copanlisib Sensitive: C3 – Early Trials	copanlisib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials	osimertinib Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	letrozole Sensitive: C3 – Early Trials	letrozole Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	trametinib + dabrafenib Sensitive: C3 – Early Trials	trametinib + dabrafenib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	GDC-0032 Sensitive: C3 – Early Trials	GDC-0032 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PIK3CA mutation PIK3CA mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	GDC-0032 Sensitive: C3 – Early Trials	GDC-0032 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + alpelisib Sensitive: C3 – Early Trials	cetuximab + alpelisib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	trastuzumab Resistant: C3 – Early Trials	trastuzumab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Solid Tumor Solid Tumor	PIK3CA mutation PIK3CA mutation	Solid Tumor Solid Tumor	LY2606368 + LY3023414 Sensitive: C3 – Early Trials	LY2606368 + LY3023414 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Resistant: C3 – Early Trials	ado-trastuzumab emtansine Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	everolimus + exemestane Sensitive: C3 – Early Trials	everolimus + exemestane Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials	FOLFOX Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	CAPOX Resistant: C3 – Early Trials	CAPOX Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials	anlotinib + sintilimab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	alpelisib Sensitive: C4 – Case Studies	alpelisib Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Ampulla of Vater Carcinoma Ampulla of Vater Carcinoma	PIK3CA mutation PIK3CA mutation	Ampulla of Vater Carcinoma Ampulla of Vater Carcinoma	everolimus Sensitive: C4 – Case Studies	everolimus Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CYH33 Sensitive: C4 – Case Studies	CYH33 Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	alpelisib Sensitive: D – Preclinical	alpelisib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PP242 Sensitive: D – Preclinical	PP242 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	crizotinib + sunitinib Sensitive: D – Preclinical	crizotinib + sunitinib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gefitinib + everolimus Sensitive: D – Preclinical	gefitinib + everolimus Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	GDC-0941 Sensitive: D – Preclinical	GDC-0941 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib + SNS-510 Sensitive: D – Preclinical	ribociclib + SNS-510 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + SNS-510 Sensitive: D – Preclinical	palbociclib + SNS-510 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	CCT128930 Sensitive: D – Preclinical	CCT128930 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	CERC-006 Sensitive: D – Preclinical	CERC-006 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	TAK-228 Sensitive: D – Preclinical	TAK-228 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Colon Cancer Colon Cancer	PIK3CA mutation PIK3CA mutation	Colon Cancer Colon Cancer	PF-05212384 + PD-0325901 Sensitive: D – Preclinical	PF-05212384 + PD-0325901 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	temsirolimus + MK-2206 Sensitive: D – Preclinical	temsirolimus + MK-2206 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: D – Preclinical	temsirolimus Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	GDC-0941 Sensitive: D – Preclinical	GDC-0941 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	RTB101 Sensitive: D – Preclinical	RTB101 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	celecoxib Sensitive: D – Preclinical	celecoxib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	trastuzumab + MEN1611 Sensitive: D – Preclinical	trastuzumab + MEN1611 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	MK-2206 Sensitive: D – Preclinical	MK-2206 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	AZD5363 Sensitive: D – Preclinical	AZD5363 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: D – Preclinical	tipifarnib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + AZD8055 Sensitive: D – Preclinical	cetuximab + AZD8055 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0032 Sensitive: D – Preclinical	GDC-0032 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Melanoma Melanoma	PIK3CA mutation PIK3CA mutation	Melanoma Melanoma	vemurafenib Resistant: D – Preclinical	vemurafenib Resistant: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	alpelisib + abemaciclib Sensitive: D – Preclinical	alpelisib + abemaciclib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	neratinib + copanlisib Sensitive: D – Preclinical	neratinib + copanlisib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	mTORC1 inhibitor Sensitive: D – Preclinical	mTORC1 inhibitor Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	epirubicin Resistant: D – Preclinical	epirubicin Resistant: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	GDC-0068 Sensitive: D – Preclinical	GDC-0068 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	PIK3CA mutation PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	PI3K inhibitor Sensitive: D – Preclinical	PI3K inhibitor Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	LY3023414 Sensitive: D – Preclinical	LY3023414 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical	ribociclib + alpelisib Sensitive: D – Preclinical